Parkinson disease (PD) is the second most common progressive neurodegenerative disorder that affects older adults. PD is characterized by a low level of dopamine being expressed in the striatum and a deterioration of dopaminergic neurons and associated neural networks in the substantia nigra of the midbrain. Current medical, surgical, and rehabilitative treatments for PD have long-term side effects and do not halt the progression of the disease. Stem cell therapies generating dopaminergic neurons from fetal brain tissue, human embryonic stem cells, human induced pluripotent stem cells, mesenchymal stem cells, human neural stem cells, direct reprogramming of somatic cells and direct reprogramming of stem cells by either gene editing, and/or gene transfer have elicited keen interest as to eventual therapeutics for Parkinson disease. Unfortunately, thus far, these experimental therapies have proved to be of limited therapeutic value in clinical trials. Using a neurotoxin-induced animal model of PD, transplantation of a naïve telomerase positive pluripotent stem cell clone demonstrated reconstitution of dopaminergic neurons and associated neural networks when stereotactically injected into neurotoxin-lesioned substantia nigra pars compactum of the ventral midbrain. Two IRB-approved clinical trials in small cohort studies (n=8 & n=4), with a combined sample size of n=12, demonstrated that intranasal infusion of autologous telomerase positive totipotent cells followed by intravenous infusion of telomerase positive pluripotent stem cells and mesodermal stem cells had a positive influence on patient symptomology with Parkinson’s Disease. No adverse effects were reported by any participant or their respective caregiver for the entire combined small cohort study (n=12). Taken together as a 2021 update of this on-going clinical study, 33% (n=4) showed moderate to no benefit of telomerase positive stem cell treatment by demonstrating a continued decline in symptoms after treatment; 33% (n=4) remained in stasis after the first month after treatment; and 33% (n=4) resolved their symptoms. The results suggest that autologous telomerase positive stem cells, TSCs, PSCs, and MesoSCs, are safe and efficacious (66%) to reduce the symptoms in participants with Parkinson’s disease.
{"title":"Treating Parkinson Disease with Autologous Telomerase-Positive Stem Cells, Update 2021","authors":"H. Young, M. Speight","doi":"10.33425/2639-9512.1059","DOIUrl":"https://doi.org/10.33425/2639-9512.1059","url":null,"abstract":"Parkinson disease (PD) is the second most common progressive neurodegenerative disorder that affects older adults. PD is characterized by a low level of dopamine being expressed in the striatum and a deterioration of dopaminergic neurons and associated neural networks in the substantia nigra of the midbrain. Current medical, surgical, and rehabilitative treatments for PD have long-term side effects and do not halt the progression of the disease. Stem cell therapies generating dopaminergic neurons from fetal brain tissue, human embryonic stem cells, human induced pluripotent stem cells, mesenchymal stem cells, human neural stem cells, direct reprogramming of somatic cells and direct reprogramming of stem cells by either gene editing, and/or gene transfer have elicited keen interest as to eventual therapeutics for Parkinson disease. Unfortunately, thus far, these experimental therapies have proved to be of limited therapeutic value in clinical trials. Using a neurotoxin-induced animal model of PD, transplantation of a naïve telomerase positive pluripotent stem cell clone demonstrated reconstitution of dopaminergic neurons and associated neural networks when stereotactically injected into neurotoxin-lesioned substantia nigra pars compactum of the ventral midbrain. Two IRB-approved clinical trials in small cohort studies (n=8 & n=4), with a combined sample size of n=12, demonstrated that intranasal infusion of autologous telomerase positive totipotent cells followed by intravenous infusion of telomerase positive pluripotent stem cells and mesodermal stem cells had a positive influence on patient symptomology with Parkinson’s Disease. No adverse effects were reported by any participant or their respective caregiver for the entire combined small cohort study (n=12). Taken together as a 2021 update of this on-going clinical study, 33% (n=4) showed moderate to no benefit of telomerase positive stem cell treatment by demonstrating a continued decline in symptoms after treatment; 33% (n=4) remained in stasis after the first month after treatment; and 33% (n=4) resolved their symptoms. The results suggest that autologous telomerase positive stem cells, TSCs, PSCs, and MesoSCs, are safe and efficacious (66%) to reduce the symptoms in participants with Parkinson’s disease.","PeriodicalId":91668,"journal":{"name":"Cell, stem cells and regenerative medicine","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73146624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alzheimer’s disease is an insidious and progressive loss of balance and cognitive memories from present time to distant past that occurs in reverse chronological order. While the cause for AD is poorly understood, the presence of tau, aggregation of beta-amyloid protein, activated microglia, and massive losses of neurons and their synaptic processes have been associated with the disease. Genetics appear to play a major role in AD, but comorbidities intervene as well. There are five drug treatments approved to control the symptoms of the disease, but none were clinically proven to alter the course or decrease the risk for AD. Death eventually occurs, usually 3-9 years after initial diagnosis. Stem cells, e.g., embryonic stem cells, induced pluripotent stem cells; mesenchymal stem cells, medicinal signaling cells, and neural stem cells have been suggested as potential treatments for AD. While clinical trials demonstrated safety of administering some of these stem cells, none demonstrated any efficacy for reversing the symptoms of AD. We report the use of adult telomerase positive stem cells as a treatment modality for reversing the symptoms of AD. In a small cohort clinical trial (n=4), there were no adverse reactions reported for any individual treated. In addition, efficacy for telomerase positive stem cells approximated 50% for reduction in symptoms of Alzheimer’s disease up to four months after their last telomerase positive stem cell treatment.
{"title":"Alzheimer’s Disease Treated with Autologous and Allogeneic TelomerasePositive Stem Cells","authors":"H. Young, M. Speight","doi":"10.33425/2639-9512.1058","DOIUrl":"https://doi.org/10.33425/2639-9512.1058","url":null,"abstract":"Alzheimer’s disease is an insidious and progressive loss of balance and cognitive memories from present time to distant past that occurs in reverse chronological order. While the cause for AD is poorly understood, the presence of tau, aggregation of beta-amyloid protein, activated microglia, and massive losses of neurons and their synaptic processes have been associated with the disease. Genetics appear to play a major role in AD, but comorbidities intervene as well. There are five drug treatments approved to control the symptoms of the disease, but none were clinically proven to alter the course or decrease the risk for AD. Death eventually occurs, usually 3-9 years after initial diagnosis. Stem cells, e.g., embryonic stem cells, induced pluripotent stem cells; mesenchymal stem cells, medicinal signaling cells, and neural stem cells have been suggested as potential treatments for AD. While clinical trials demonstrated safety of administering some of these stem cells, none demonstrated any efficacy for reversing the symptoms of AD. We report the use of adult telomerase positive stem cells as a treatment modality for reversing the symptoms of AD. In a small cohort clinical trial (n=4), there were no adverse reactions reported for any individual treated. In addition, efficacy for telomerase positive stem cells approximated 50% for reduction in symptoms of Alzheimer’s disease up to four months after their last telomerase positive stem cell treatment.","PeriodicalId":91668,"journal":{"name":"Cell, stem cells and regenerative medicine","volume":"120 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77191683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Loss of visual acuity may result from genetics, cancer, metabolic disorders, trauma, or aging. Adult telomerase- positive totipotent stem cells have been identified in multiple species of animals, including humans. Characterization studies to identify differentiated cells utilized three clones of adult-derived totipotent stem cells (TSCs) and treated them with induction factors consisting of chemical mediators, human recombinant proteins and cell-specific exosomes. Results demonstrated that the TSC clones would form cells expressing phenotypic markers of the neural ectodermal lineage, e.g., ectodermal stem cells, ectodermal progenitor stem cells, neurons, ganglion cells, glial cells, and neural crest derivatives. Autologous TSCs were shown to partially restore function in clinical trial participants with Alzheimer’s disease, Parkinson’s disease, and Age-related Dry Macular Degeneration. It was hypothesized that following intranasal infusion, TSCs would migrate to areas associated with the visual pathway to repair and/or regenerate damaged and/or missing cells, thus restoring function. In this small cohort study (n=1), the presenting symptom for a 17-year-old female was total bilateral visual impairment (complete blindness) of 13-years duration, due to severe head trauma from an automobile accident at four years of age. Following her first TSC treatment, she could see indistinct black shapes on a background of a dark shade of gray. Following her second TSC treatment she could see background as a lighter shade of gray and a black square with slightly more distinct borders. No adverse effects were noted after either autologous TSC treatment. These results suggest that two treatments with TSCs were both safe and somewhat efficacious in helping to partially restore her ‘night’ vision.
{"title":"Blunt Force Trauma-Induced Total Bilateral Visual Impairment of 13 Years Duration Treated with Autologous Telomerase-Positive Stem Cells","authors":"H. Young, M. Speight","doi":"10.33425/2639-9512.1063","DOIUrl":"https://doi.org/10.33425/2639-9512.1063","url":null,"abstract":"Loss of visual acuity may result from genetics, cancer, metabolic disorders, trauma, or aging. Adult telomerase- positive totipotent stem cells have been identified in multiple species of animals, including humans. Characterization studies to identify differentiated cells utilized three clones of adult-derived totipotent stem cells (TSCs) and treated them with induction factors consisting of chemical mediators, human recombinant proteins and cell-specific exosomes. Results demonstrated that the TSC clones would form cells expressing phenotypic markers of the neural ectodermal lineage, e.g., ectodermal stem cells, ectodermal progenitor stem cells, neurons, ganglion cells, glial cells, and neural crest derivatives. Autologous TSCs were shown to partially restore function in clinical trial participants with Alzheimer’s disease, Parkinson’s disease, and Age-related Dry Macular Degeneration. It was hypothesized that following intranasal infusion, TSCs would migrate to areas associated with the visual pathway to repair and/or regenerate damaged and/or missing cells, thus restoring function. In this small cohort study (n=1), the presenting symptom for a 17-year-old female was total bilateral visual impairment (complete blindness) of 13-years duration, due to severe head trauma from an automobile accident at four years of age. Following her first TSC treatment, she could see indistinct black shapes on a background of a dark shade of gray. Following her second TSC treatment she could see background as a lighter shade of gray and a black square with slightly more distinct borders. No adverse effects were noted after either autologous TSC treatment. These results suggest that two treatments with TSCs were both safe and somewhat efficacious in helping to partially restore her ‘night’ vision.","PeriodicalId":91668,"journal":{"name":"Cell, stem cells and regenerative medicine","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84843990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ali Awad Hamoud Aljeboory, Rafid Mohammed Mohammed Hashim, Yahya Yahya Zaki Farid
From traditional and folk medicine, the fruit of Capparis used as antiseptic for intestinal dysentery and as protective for the liver from diseases in addition it is used as aphrodisiac and antihypertensive agent in addition as anticancer so as we know that natural product still a bank of new drug resources for the following reasons; these are a target for production by biotechnology. In addition, they are as a source of new lead compounds of novel chemical structure, which act as a tool for invention of new drug using nanoscince in medicine. There is a third reason as active ingredients of useful treatment divided from traditional medicine. As we know the drugs which manufacturing from bioactive, materials are cheap and available and not polluted as the chemical synthetic drugs and do not need-sophisticated technology. In this study we use fruits and leaves of Capparis dried and milled then extracted with alcohol 80% in addition deal with different organic solvent and get rid of chlorophyll and caryophilline and phytochemical studies by using liquid-liquid HPLC and we managed to extract quercitin and quercitrin in addition to proteins. The last product was anti-oxidant compared with racemic vitamin C using Noradrenaline as a test for the oxidation. Lastly, we see the activity of these materials as potent activator to the male compared with Sildenafil. The Capparis increase the activity twice the effect of sildenafil, And Tadalafil.
{"title":"Capparis Spinosa is an Alternative Drug for Vitality","authors":"Ali Awad Hamoud Aljeboory, Rafid Mohammed Mohammed Hashim, Yahya Yahya Zaki Farid","doi":"10.33425/2639-9512.1060","DOIUrl":"https://doi.org/10.33425/2639-9512.1060","url":null,"abstract":"From traditional and folk medicine, the fruit of Capparis used as antiseptic for intestinal dysentery and as protective for the liver from diseases in addition it is used as aphrodisiac and antihypertensive agent in addition as anticancer so as we know that natural product still a bank of new drug resources for the following reasons; these are a target for production by biotechnology. In addition, they are as a source of new lead compounds of novel chemical structure, which act as a tool for invention of new drug using nanoscince in medicine. There is a third reason as active ingredients of useful treatment divided from traditional medicine. As we know the drugs which manufacturing from bioactive, materials are cheap and available and not polluted as the chemical synthetic drugs and do not need-sophisticated technology. In this study we use fruits and leaves of Capparis dried and milled then extracted with alcohol 80% in addition deal with different organic solvent and get rid of chlorophyll and caryophilline and phytochemical studies by using liquid-liquid HPLC and we managed to extract quercitin and quercitrin in addition to proteins. The last product was anti-oxidant compared with racemic vitamin C using Noradrenaline as a test for the oxidation. Lastly, we see the activity of these materials as potent activator to the male compared with Sildenafil. The Capparis increase the activity twice the effect of sildenafil, And Tadalafil.","PeriodicalId":91668,"journal":{"name":"Cell, stem cells and regenerative medicine","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87804831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A 36-year-old paraplegic female presented to the clinic for bi-monthly pain management below thoracic level, T12. She was absent of cutaneous sensation below level of T12, absent of bladder/rectum function, absent genital function, and could not move around without the use of a wheelchair. She displayed anxiety, depression, and decreased feeling of self-worth. Her intense pain was due to a traumatic spinal cord crush injury from a car accident 12 years previously. To date, no effective pharmacological or regenerative treatment has been developed to treat chronic spinal cord injuries. Advances in stem cell technologies (e.g., embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), neural stem cells (NSCs), NSCs induced from either iPSCs or ESCs, mesenchymal stem cells, medicinal signaling cells, etc.), biomaterials, immune engineering, and nanotechnologies have been applied to regenerative therapies following subacute spinal cord injuries. Although these therapies have proven safe for subacute spinal cord injury in animal models, their efficacy in clinical trials to date has not been demonstrated. The participant was presented with opportunity to join a clinical trial using autologous adult-derived telomerase positive stem cells for amelioration of her neurogenic problems. She agreed to the trial because she wanted to walk. Her first autologous stem cell transplant did not ameliorate any of her symptoms. In retrospect, this was due to the anesthetic having a 100% kill ratio for telomerase positive stem cells. Switching to an anesthetic with a 0% kill ratio allowed the telomerase positive stem cells the potential to restore neurogenic function as previously noted for Parkinson disease, age-related dry macular degeneration, and Alzheimer’s disease. Following two telomerase positive stem cell treatments there was restoration of sensation from below her umbilicus to just proximal to her knee joints and restoration of function of her urinary bladder and rectum. Due to the limited time frame following her treatments (e.g., four months), no sustained voluntary control was seen in the musculature of her lower extremities. Her inability to walk following two telomerase positive stem cell treatments prompted her to drop out of the study. Due to restoration of function to damaged structures of the central and peripheral nervous system after following telomerase positive stem cell transplants in this chronic spinal cord injured patient, suggest that TSCs, PSCs, and MesoSCs might have been involved in this restorative process. Since no adverse events were reported during her study, autologous telomerase positive stem cells appeared to be safe for administration. And with restoration of the neurogenic activities during the limited time frame of treatment, administration of telomerase positive stem cells appears to be efficacious in their activities to restore neurogenic function to the tissues absent of those activities for 12 years duration.
{"title":"Traumatic Spinal Cord Injury at T12 Causing Complete Paraplegia for 12-Years Duration Treated with Autologous Telomerase Positive Stem Cells","authors":"H. Young, M. Speight","doi":"10.33425/2639-9512.1061","DOIUrl":"https://doi.org/10.33425/2639-9512.1061","url":null,"abstract":"A 36-year-old paraplegic female presented to the clinic for bi-monthly pain management below thoracic level, T12. She was absent of cutaneous sensation below level of T12, absent of bladder/rectum function, absent genital function, and could not move around without the use of a wheelchair. She displayed anxiety, depression, and decreased feeling of self-worth. Her intense pain was due to a traumatic spinal cord crush injury from a car accident 12 years previously. To date, no effective pharmacological or regenerative treatment has been developed to treat chronic spinal cord injuries. Advances in stem cell technologies (e.g., embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), neural stem cells (NSCs), NSCs induced from either iPSCs or ESCs, mesenchymal stem cells, medicinal signaling cells, etc.), biomaterials, immune engineering, and nanotechnologies have been applied to regenerative therapies following subacute spinal cord injuries. Although these therapies have proven safe for subacute spinal cord injury in animal models, their efficacy in clinical trials to date has not been demonstrated. The participant was presented with opportunity to join a clinical trial using autologous adult-derived telomerase positive stem cells for amelioration of her neurogenic problems. She agreed to the trial because she wanted to walk. Her first autologous stem cell transplant did not ameliorate any of her symptoms. In retrospect, this was due to the anesthetic having a 100% kill ratio for telomerase positive stem cells. Switching to an anesthetic with a 0% kill ratio allowed the telomerase positive stem cells the potential to restore neurogenic function as previously noted for Parkinson disease, age-related dry macular degeneration, and Alzheimer’s disease. Following two telomerase positive stem cell treatments there was restoration of sensation from below her umbilicus to just proximal to her knee joints and restoration of function of her urinary bladder and rectum. Due to the limited time frame following her treatments (e.g., four months), no sustained voluntary control was seen in the musculature of her lower extremities. Her inability to walk following two telomerase positive stem cell treatments prompted her to drop out of the study. Due to restoration of function to damaged structures of the central and peripheral nervous system after following telomerase positive stem cell transplants in this chronic spinal cord injured patient, suggest that TSCs, PSCs, and MesoSCs might have been involved in this restorative process. Since no adverse events were reported during her study, autologous telomerase positive stem cells appeared to be safe for administration. And with restoration of the neurogenic activities during the limited time frame of treatment, administration of telomerase positive stem cells appears to be efficacious in their activities to restore neurogenic function to the tissues absent of those activities for 12 years duration.","PeriodicalId":91668,"journal":{"name":"Cell, stem cells and regenerative medicine","volume":"123 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76262604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Stoltz, Y. Rémond, D. George, J. Magdalou, Yueying Li, Zhongchao Han, Lei Zhang, N. Isla, Yun Chen
Almost all cells in the human body are subjected to mechanical stresses. These forces can vary from a few Pascals (shear stress) to some mega Pascals (on hip cartilage). It is now well known that mechanical forces have a decisive effect on cellular physiology. In 1880, W. Roux introduced the concept of functional adaptation; which can be defined as a quantitative autoregulation controlled by stimuli like mechanical forces. These stresses influence functionality and cellular metabolism and can lead to appropriate tissue remodelling by triggering a cascade of reactions (mechanotransduction), being the signal for the adaptation of cells and tissues. However, although the main biological effects of mechanical forces are well documented, the relation between mechanical forces and physiological phenomena is largely unknown. In this paper, some effects of mechanical stresses on different cells (mesenchymal stem cells, bone cells, chondrocyte, endothelial cells, vascular or muscular cells, etc.) are summarized.
{"title":"The Mechanoadaptation Concept of Cells","authors":"J. Stoltz, Y. Rémond, D. George, J. Magdalou, Yueying Li, Zhongchao Han, Lei Zhang, N. Isla, Yun Chen","doi":"10.3233/BHR210010","DOIUrl":"https://doi.org/10.3233/BHR210010","url":null,"abstract":"Almost all cells in the human body are subjected to mechanical stresses. These forces can vary from a few Pascals (shear stress) to some mega Pascals (on hip cartilage). It is now well known that mechanical forces have a decisive effect on cellular physiology. In 1880, W. Roux introduced the concept of functional adaptation; which can be defined as a quantitative autoregulation controlled by stimuli like mechanical forces. These stresses influence functionality and cellular metabolism and can lead to appropriate tissue remodelling by triggering a cascade of reactions (mechanotransduction), being the signal for the adaptation of cells and tissues. However, although the main biological effects of mechanical forces are well documented, the relation between mechanical forces and physiological phenomena is largely unknown. In this paper, some effects of mechanical stresses on different cells (mesenchymal stem cells, bone cells, chondrocyte, endothelial cells, vascular or muscular cells, etc.) are summarized.","PeriodicalId":91668,"journal":{"name":"Cell, stem cells and regenerative medicine","volume":"16 1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85296901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Age-related macular degeneration (AMD) is an insidious disease characterized by gradual worsening of symptoms, which in time results in a loss of visual acuity in the central area of vision. Macular degeneration does not result in complete blindness, because peripheral vision remains. However, loss of central vision can make it difficult to perform daily activities, such as reading, driving, recognizing faces, etc. There are two forms of macular degeneration, wet and dry. Wet macular degeneration occurs in about 20% of the cases and can be treated pharmacologically. Dry macular degeneration occurs in about 80% of all cases. It has no known treatment or cure. Currently, the Holy Grail for regenerative medicine for diseases and/or disorders with no known cure involves the use of stem cells. Three types of stem cells have been proposed to treat individuals with macular degeneration, e.g., mesenchymal stem cells, embryonic stem cells, and induced pluripotent stem cells. We propose a fourth possibility; endogenous adult-derived telomerase-positive totipotent stem cells (TSCs). Autologous TSCs were used to treat four individuals with macular degeneration that had lost their central visual acuity. Two subjects had their central visual acuity restored. The third had serious heart comorbidity and the TSCs treated their body instead, and the fourth individual was non-compliant. The results demonstrated both safety and efficacy (50%) for treating macular degeneration with TSCs.
{"title":"Age-Related Macular Degeneration Treated with Autologous TelomerasePositive Totipotent Stem Cells","authors":"H. Young, M. Speight","doi":"10.33425/2639-9512.1055","DOIUrl":"https://doi.org/10.33425/2639-9512.1055","url":null,"abstract":"Age-related macular degeneration (AMD) is an insidious disease characterized by gradual worsening of symptoms, which in time results in a loss of visual acuity in the central area of vision. Macular degeneration does not result in complete blindness, because peripheral vision remains. However, loss of central vision can make it difficult to perform daily activities, such as reading, driving, recognizing faces, etc. There are two forms of macular degeneration, wet and dry. Wet macular degeneration occurs in about 20% of the cases and can be treated pharmacologically. Dry macular degeneration occurs in about 80% of all cases. It has no known treatment or cure. Currently, the Holy Grail for regenerative medicine for diseases and/or disorders with no known cure involves the use of stem cells. Three types of stem cells have been proposed to treat individuals with macular degeneration, e.g., mesenchymal stem cells, embryonic stem cells, and induced pluripotent stem cells. We propose a fourth possibility; endogenous adult-derived telomerase-positive totipotent stem cells (TSCs). Autologous TSCs were used to treat four individuals with macular degeneration that had lost their central visual acuity. Two subjects had their central visual acuity restored. The third had serious heart comorbidity and the TSCs treated their body instead, and the fourth individual was non-compliant. The results demonstrated both safety and efficacy (50%) for treating macular degeneration with TSCs.","PeriodicalId":91668,"journal":{"name":"Cell, stem cells and regenerative medicine","volume":"138 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81614427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Trainini, Gabriel Volman, N. Lago, J. Bordone, Oscar Ectchegoyen, F. Villasante, Facundo Heredia, Yanina Huamanchuco, J. Docampo, Bastarrica María Elena
{"title":"Autologous Mesenchymal Stem Cells for the Treatment of Amyotrophic Lateral Sclerosis","authors":"J. Trainini, Gabriel Volman, N. Lago, J. Bordone, Oscar Ectchegoyen, F. Villasante, Facundo Heredia, Yanina Huamanchuco, J. Docampo, Bastarrica María Elena","doi":"10.33425/2639-9512.1053","DOIUrl":"https://doi.org/10.33425/2639-9512.1053","url":null,"abstract":"","PeriodicalId":91668,"journal":{"name":"Cell, stem cells and regenerative medicine","volume":"51 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85229879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
D. Klokol, Lingeswran Nallenthiran, Mike K. S. Chan, M. Wong, V. Chernykh, S. Yefimov, Y. Nalapko, M. Emelianova
{"title":"Holistic Regenerative Medicine and Cell Therapy in Treatment of Diabetes Mellitus: State of The Art Medicine and A Game Changer","authors":"D. Klokol, Lingeswran Nallenthiran, Mike K. S. Chan, M. Wong, V. Chernykh, S. Yefimov, Y. Nalapko, M. Emelianova","doi":"10.33425/2639-9512.1052","DOIUrl":"https://doi.org/10.33425/2639-9512.1052","url":null,"abstract":"","PeriodicalId":91668,"journal":{"name":"Cell, stem cells and regenerative medicine","volume":"59 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75368939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Extracorporeal Shock Wave Therapy (Eswt) For the Treatment of Chronic, Non-Healing Wounds: A Case Series","authors":"Belinda Marcus","doi":"10.33425/2639-9512.1057","DOIUrl":"https://doi.org/10.33425/2639-9512.1057","url":null,"abstract":"","PeriodicalId":91668,"journal":{"name":"Cell, stem cells and regenerative medicine","volume":"63 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81415589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：